Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-25 @ 12:03 AM
Ignite Modification Date: 2025-12-25 @ 10:02 PM
NCT ID: NCT00670358
Term: Hemoglobin decreased
Organ System: Blood and lymphatic system disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: CTCAE 3
Notes: None
Study: NCT00670358
Study Brief: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 22 3 3 View
EG001 20 3 3 View
EG002 40 6 6 View
EG003 434 75 76 View
EG004 260 39 39 View
EG005 72 10 10 View